Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Cancer Immunol Res. 2021 Dec;9(12):1413–1424. doi: 10.1158/2326-6066.CIR-21-0754

Figure 4: Setdb1 loss synergizes with anti–PD-L1 in reducing tumor burden.

Figure 4:

A, Schematic of the experimental design using the ID8 syngeneic orthotopic mouse ovarian cancer model. B, Reproductive tracts with tumors from the indicated treatment groups were dissected at the end of treatment (n=5 mice per group). C, The weights of tumors dissected from the indicated groups were measured as a surrogate for tumor burden. P-values were calculated using a two-tailed t test. Combination index (CI) for Setdb1 loss and anti–PD-L1 is 0.82 (<1), which indicates synergy between Setdb1 loss and anti-PD1 combination. D, E, Infiltration of CD8+ T cells (D) and Granzyme B+/CD8+ T cells (E) in the tumors dissected from the indicated treatment groups were analyzed by flow cytometry (n = 5 mice per group). Data represent mean ± SEM, P values were calculated using a two-tailed t test.